天津医药

• 临床研究 • 上一篇    下一篇

双联抗血小板药物在2004例PCI患者中致上消化道出血的危险因素分析

冯雪1,张志广2,李熳3   

  1. 1. 天津医科大学第二医院消化科
    2. 天津医大二院消化科
    3. 天津医科大学第二医院
  • 收稿日期:2013-05-22 修回日期:2013-10-22 出版日期:2014-03-15 发布日期:2014-03-15
  • 通讯作者: 张志广

Risk Factors Analysis Of Upper Gastrointestinal Hemorrhage Induced by Dual Anti-platelet Treatment in PCI Patient

Xue FENG 2,li man2   

  • Received:2013-05-22 Revised:2013-10-22 Published:2014-03-15 Online:2014-03-15

PDF (PC)

2977

摘要： 摘要: 目的 探讨双联抗血小板药物在PCI患者中致上消化道出血的发生情况及其相关危险因素。方法 对2004例服用双联抗血小板药物的PCI患者的临床资料, 内容包括: 性别、年龄、BMI、服药时间、既往消化道病史、吸烟史、饮酒史、高血压病史、糖尿病病史、脑血管病史、联用PPI及实验室化验指标（PLT、CR、HB）异常等情况。结果 年龄≧65岁、吸烟史、高血压病史、实验室化验指标（PLT、CR、HB）异常是双联抗血小板药物致PCI患者上消化道出血的危险因素(P<0. 05); 联用PPI后, 出血发生率明显减少(P<0. 05)。结论 双联抗血小板药物致上消化道出血的发生率与患者的年龄、吸烟史、高血压病史、实验室化验指标PLT、CR、HB异常有关。及时辅以PPI治疗, 可有效减少双联抗血小板药物致上消化道出血的发生。

关键词: 双联抗血小板药物, 上消化道出血, 危险因素

Abstract: Abstract: Objective To investigate the risk factors of dual anti-platelet treatment related upper gastrointestinal hemorrhage. Methods 2004 patients taking dual anti-platelet treatment for coronary heart disease were retrospectively analyzed and followed up. Results The incidence of dual anti-platelet treatment related upper gastrointestinal bleeding was associated with age, smoke, history of hypertension , abnormal test parameters and the use of PPI protective acid-suppressing agents. Conclusion The long term use of dual anti-platelet treatment can increase the risk upper gastrointestinal bleeding in the elderly patients, in addition to smoke, history of hypertension , abnormal test parameters. Gastric mucosal protective or acid suppressing agents is effective in reducing the occurrence of upper gastrointestinal bleeding.

Key words: Dual anti-platelet treatment, Upper gastrointestinal bleeding, Risk factor